

# SAFETY DATA SHEET



## Finasteride (1%) Formulation



Version 8.1      Revision Date: 10.10.2020      SDS Number: 49629-00017      Date of last issue: 23.03.2020  
Date of first issue: 26.01.2015

---

### SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Finasteride (1%) Formulation

#### Manufacturer or supplier's details

Company : Organon & Co.  
Address : Rua Treze de Maio, 1161  
Campinas, São Paulo, Brazil B-2220  
Telephone : 551-430-6000  
Emergency telephone : 215-631-6999  
E-mail address : EHSSTEWARD@organon.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical


---

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS Classification in accordance with ABNT NBR 14725 Standard

Reproductive toxicity : Category 1B  
Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Testis)  
Long-term (chronic) aquatic hazard : Category 3

#### GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms : 

Signal Word : Danger

Hazard Statements : H360D May damage the unborn child.  
H373 May cause damage to organs (Testis) through prolonged or repeated exposure if swallowed.  
H412 Harmful to aquatic life with long lasting effects.

Precautionary Statements : **Prevention:**  
P201 Obtain special instructions before use.  
P260 Do not breathe dust.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

---

## Finasteride (1%) Formulation

Version 8.1      Revision Date: 10.10.2020      SDS Number: 49629-00017      Date of last issue: 23.03.2020  
Date of first issue: 26.01.2015

**Response:**

P308 + P313 IF exposed or concerned: Get medical advice/attention.

**Storage:**

P405 Store locked up.

**Other hazards which do not result in classification**

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Cellulose	9004-34-6		>= 5 -< 10
Starch	9005-25-8		>= 5 -< 10
Finasteride	98319-26-7	Acute toxicity (Oral), Category 4 Reproductive toxicity, Category 1B Specific target organ toxicity - repeated exposure (Oral) (Testis), Category 1 Short-term (acute) aquatic hazard, Category 3 Long-term (chronic) aquatic hazard, Category 1	>= 1 -< 2,5
Titanium dioxide	13463-67-7	Carcinogenicity (Inhalation), Category 2	>= 0,1 -< 1

**SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.

## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
8.1	10.10.2020	49629-00017	Date of first issue: 26.01.2015

---

In case of eye contact	:	Thoroughly clean shoes before reuse. If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	May damage the unborn child. May cause damage to organs through prolonged or repeated exposure if swallowed. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

---

**SECTION 5. FIRE-FIGHTING MEASURES**

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Metal oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

---

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for	:	Sweep up or vacuum up spillage and collect in suitable

## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
8.1	10.10.2020	49629-00017	Date of first issue: 26.01.2015

---

containment and cleaning up container for disposal.  
 Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
 Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
 Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
 Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

**SECTION 7. HANDLING AND STORAGE**

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	:	Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
Conditions for safe storage	:	Keep in properly labeled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.
Materials to avoid	:	Do not store with the following product types: Strong oxidizing agents Organic peroxides

## Finasteride (1%) Formulation

Version 8.1      Revision Date: 10.10.2020      SDS Number: 49629-00017      Date of last issue: 23.03.2020  
Date of first issue: 26.01.2015

Explosives  
Gases

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
Starch	9005-25-8	TWA	10 mg/m <sup>3</sup>	ACGIH
Finasteride	98319-26-7	TWA	0.5 µg/m <sup>3</sup> (OEB 5)	Internal
		Wipe limit	5 µg/100 cm <sup>2</sup>	Internal
Titanium dioxide	13463-67-7	TWA	10 mg/m <sup>3</sup> (Titanium dioxide)	ACGIH

**These substance(s) are inextricably bound in the product and therefore do not contribute to a dust inhalation hazard.**

Titanium dioxide

**Engineering measures** : Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted. Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

**Personal protective equipment**

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

# SAFETY DATA SHEET



## Finasteride (1%) Formulation



Version 8.1      Revision Date: 10.10.2020      SDS Number: 49629-00017      Date of last issue: 23.03.2020  
Date of first issue: 26.01.2015

---

disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	tan
Odor	:	odorless
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	log Pow: 3,5 pH: 7 Active ingredient
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available

## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
8.1	10.10.2020	49629-00017	Date of first issue: 26.01.2015

---

Viscosity		
Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle size	:	No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity	:	Acute toxicity estimate: > 5.000 mg/kg Method: Calculation method
---------------------	---	--

**Components:****Cellulose:**

Acute oral toxicity	:	LD50 (Rat): > 5.000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5,8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2.000 mg/kg

**Starch:**

Acute oral toxicity	:	LD50 (Rat): > 5.000 mg/kg
Acute dermal toxicity	:	LD50 (Rabbit): > 2.000 mg/kg

## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
8.1	10.10.2020	49629-00017	Date of first issue: 26.01.2015

---

**Finasteride:**

Acute oral toxicity : LD50 (Rat): 373 - 828 mg/kg  
LD50 (Mouse): 486 mg/kg

**Titanium dioxide:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg  
Acute inhalation toxicity : LC50 (Rat): > 6,82 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Assessment: The substance or mixture has no acute inhalation toxicity

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Finasteride:**

Species : Rabbit  
Result : No skin irritation

**Titanium dioxide:**

Species : Rabbit  
Result : No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Starch:**

Species : Rabbit  
Result : No eye irritation

**Finasteride:**

Species : Rabbit  
Remarks : slight irritation

**Titanium dioxide:**

Species : Rabbit  
Result : No eye irritation

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.



## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
8.1	10.10.2020	49629-00017	Date of first issue: 26.01.2015

---

### Components:

#### **Starch:**

Test Type	: Maximization Test
Routes of exposure	: Skin contact
Species	: Guinea pig
Result	: negative

#### **Titanium dioxide:**

Test Type	: Local lymph node assay (LLNA)
Routes of exposure	: Skin contact
Species	: Mouse
Result	: negative

#### **Germ cell mutagenicity**

Not classified based on available information.

### Components:

#### **Cellulose:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative
	Test Type: In vitro mammalian cell gene mutation test
	Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
	Species: Mouse
	Application Route: Ingestion
	Result: negative

#### **Starch:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative

#### **Finasteride:**

Genotoxicity in vitro	: Test Type: Chromosome aberration test in vitro
	Result: positive
	Test Type: In vitro mammalian cell gene mutation test
	Result: negative
	Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative
	Test Type: Alkaline elution assay
	Result: negative
Genotoxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
	Application Route: Oral

## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
8.1	10.10.2020	49629-00017	Date of first issue: 26.01.2015

---

Result: negative

### Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
Species: Mouse  
Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### Cellulose:

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

#### Finasteride:

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
: 160 mg/kg body weight  
Result : negative  
Target Organs : Testes  
Remarks : Benign tumor(s)

Species : Mouse  
Application Route : Ingestion  
Exposure time : 19 month(s)  
Result : negative  
Target Organs : Testes  
Remarks : Benign tumor(s)

#### Titanium dioxide:

Species : Rat  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 2 Years  
Method : OECD Test Guideline 453  
Result : positive  
Remarks : The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in inhalation studies with animals.

### Reproductive toxicity

May damage the unborn child.

## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
8.1	10.10.2020	49629-00017	Date of first issue: 26.01.2015

---

### Components:

#### **Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

#### **Finasteride:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rabbit  
Application Route: Oral  
Fertility: NOAEL: 80 mg/kg body weight  
Result: No effects on fertility.

Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Fertility: LOAEL: 80 mg/kg body weight  
Result: positive  
Remarks: There is no evidence that these findings are relevant to humans.

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Developmental Toxicity: LOAEL: 0,003 mg/kg body weight  
Result: Teratogenic effects., Embryotoxic effects.

Test Type: Embryo-fetal development  
Species: Monkey  
Application Route: Ingestion  
Developmental Toxicity: LOAEL: 2 mg/kg body weight  
Result: Teratogenic effects.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

#### **STOT-single exposure**

Not classified based on available information.

#### **STOT-repeated exposure**

May cause damage to organs (Testis) through prolonged or repeated exposure if swallowed.

### Components:

#### **Finasteride:**

Routes of exposure : Ingestion  
Target Organs : Testis

## Finasteride (1%) Formulation

Version 8.1      Revision Date: 10.10.2020      SDS Number: 49629-00017      Date of last issue: 23.03.2020  
Date of first issue: 26.01.2015

---

Assessment : Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Cellulose:**

Species : Rat  
NOAEL :  $\geq 9.000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

**Starch:**

Species : Rat  
NOAEL :  $\geq 2.000$  mg/kg  
Application Route : Skin contact  
Exposure time : 28 Days  
Method : OECD Test Guideline 410

**Finasteride:**

Species : Rat  
NOAEL : 20 mg/kg  
LOAEL : 40 mg/kg  
Application Route : Oral  
Exposure time : 1 y  
Target Organs : Testis

Species : Dog  
NOAEL : 45 mg/kg  
Application Route : Oral  
Exposure time : 1 y  
Target Organs : Testis

**Titanium dioxide:**

Species : Rat  
NOAEL : 24.000 mg/kg  
Application Route : Ingestion  
Exposure time : 28 Days

Species : Rat  
NOAEL : 10 mg/m<sup>3</sup>  
Application Route : inhalation (dust/mist/fume)  
Exposure time : 2 y

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Finasteride:**

## Finasteride (1%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
8.1	10.10.2020	49629-00017	Date of first issue: 26.01.2015

Ingestion : Symptoms: breast tenderness, breast enlargement, impotence, lip swelling, skin rash

### SECTION 12. ECOLOGICAL INFORMATION

#### Ecotoxicity

##### Components:

##### **Cellulose:**

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

##### **Finasteride:**

Toxicity to fish : LC50 (*Oncorhynchus mykiss* (rainbow trout)): 20,4 mg/l  
Exposure time: 96 h  
Method: FDA 4.11

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): 17,8 mg/l  
Exposure time: 48 h  
Method: FDA 4.08

Toxicity to algae/aquatic plants : NOEC (*Pseudokirchneriella subcapitata* (green algae)): 49 mg/l  
Exposure time: 14 h  
Method: FDA 4.01

Toxicity to fish (Chronic toxicity) : NOEC (*Oryzias latipes* (Orange-red killifish)): 0,05 mg/l  
Exposure time: 105 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (*Daphnia magna* (Water flea)): 0,12 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity) : 1

##### **Titanium dioxide:**

Toxicity to fish : LC50 (*Oncorhynchus mykiss* (rainbow trout)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): > 100 mg/l  
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (*Skeletonema costatum* (marine diatom)): > 10.000 mg/l  
Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1.000 mg/l  
Exposure time: 3 h  
Method: OECD Test Guideline 209

## Finasteride (1%) Formulation

Version 8.1      Revision Date: 10.10.2020      SDS Number: 49629-00017      Date of last issue: 23.03.2020  
Date of first issue: 26.01.2015

---

**Persistence and degradability****Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

**Finasteride:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 0 %  
Exposure time: 7 d  
Method: FDA 3.11

Stability in water : Hydrolysis: 0 %(5 d)  
Method: FDA 3.09

**Bioaccumulative potential****Components:****Finasteride:**

Partition coefficient: n-octanol/water : log Pow: 3,57

**Mobility in soil**

No data available

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Domestic regulation**

# SAFETY DATA SHEET



## Finasteride (1%) Formulation



Version 8.1      Revision Date: 10.10.2020      SDS Number: 49629-00017      Date of last issue: 23.03.2020  
Date of first issue: 26.01.2015

---

### ANTT

Not regulated as a dangerous good

---

## SECTION 15. REGULATORY INFORMATION

### Safety, health and environmental regulations/legislation specific for the substance or mixture

National List of Carcinogenic Agents for Humans - (LINACH)

Group 2B: Possibly carcinogenic to humans

Titanium dioxide      13463-67-7

Brazil. List of chemicals controlled by the Federal Police : Not applicable

### International Regulations

#### The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

---

## SECTION 16. OTHER INFORMATION

### Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AllC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Con-

# SAFETY DATA SHEET



## Finasteride (1%) Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
8.1	10.10.2020	49629-00017	Date of first issue: 26.01.2015

---

centration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8